Augmenix, Inc. is a privately held medical device company focused on the development and commercialization of radiation oncology and urology products using its proprietary hydrogel technology. The company is using this technology to develop products that decrease unintended radiation damage to normal organs during cancer radiation therapy and to mark soft tissue.

The SpaceOAR System (OAR stands for ñorgan at riskî) is an absorbable hydrogel that temporarily moves the rectum away from the prostate and the high intensity radiation zone, protecting the rectum in men undergoing radiation therapy for prostate cancer. Clinically proven, the created space reduces rectal radiation injury and the resulting long term complications. It is the first and only prostate cancer spacing device to receive Food and Drug Administration (FDA) clearance.

Additionally, Augmenix has developed an absorbable tissue marker that marks soft tissue for a surgical procedure or future surgical procedures. TraceIT Tissue Marker is visible on multi-modality imaging allowing for improved tissue marking.

This technology, licensed from Incept, LLC, comes from a line of products that have made a meaningful impact in the areas of neurosurgery and interventional cardiology. Augmenix is bringing this technology to the field of radiation oncology through high quality investors and an experienced management team.

Augmenix, SpaceOAR, and SpaceOAR logo are registered trademarks of Augmenix, Inc.